Announcements Trials
Browse Landscape

Phase

Phase NA 45Phase 2 31Phase 3 9Phase 1 9Phase 1/2 4Phase 2/3 3

Status

Recruiting 2Unknown 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Thoracic 1Breast 1

Conditions

Prostatic Neoplasms 3Carcinoma, Hepatocellular 2Breast Neoplasms 2Stomach Neoplasms 1Pancreatic Adenocarcinoma 1Pain 1Neoplasm Metastasis 1NSCLC 1Lymphatic Metastasis 1Colorectal Neoplasms 1Castration-resistant Prostate Cancer Patients with Oligometastases 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma 1

Interventions

Docetaxel 7acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 5Prednisone 5Androgen Antagonists 5gallium 68 PSMA-11 4enzalutamide 3bicalutamide 3Triptorelin Pamoate 3Radiosurgery 3Leuprolide 3Goserelin 32-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 3abiraterone 2Zoledronic Acid 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Mitoxantrone 2Flutamide 2Celecoxib 2Abiraterone Acetate 2satraplatin 1relugolix 1pertuzumab 1nilutamide 1maltodextrin 1luprolide acetate gel depot 1histrelin 1genistein combined polysaccharide 1fluciclovine F-18 1darolutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × Prostatic Neoplasms × Radiosurgery × Clear all
NCT07426055 2026-03-23

PRO-BOOST-LC

Affidea Nu-med Center of Oncological DIagnostics and Therapy

Phase 2/3 Recruiting
1,200 enrolled
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT04654338 2023-06-27

EARTH

Sunnybrook Health Sciences Centre

Phase 2/3 Recruiting
30 enrolled
Genitourinary

Prostatic Neoplasms

NCT02759783 2019-08-21

CORE

Royal Marsden NHS Foundation Trust

Phase 2/3 Unknown
245 enrolled
BreastGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡